诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

盘后交易 03-31 17:48:31 EDT

152.75

+2.39

+1.59%

盘后152.75

+0.000.00%

17:33 EDT

最高152.86	最低150.52	成交量200.30万
今开151.58	昨收150.36	日振幅1.56%
总市值2,914亿	流通市值2,774亿	总股本19.08亿
成交额3.04亿	换手率0.11%	流通股本18.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":152.75,"timestamp":1774987200000,"preClose":150.36,"halted":0,"volume":2003002,"hourTrading":{"tag":"盘后","latestPrice":152.75,"preClose":152.75,"latestTime":"17:33 EDT","volume":21512,"amount":3285958.6453600004,"timestamp":1774992792108,"change":0,"changeRate":0,"amplitude":0.001702},"delay":0,"changeRate":0.015895184889598204,"floatShares":1816000000,"shares":1907999999,"eps":7.15,"marketStatus":"盘后交易","change":2.39,"latestTime":"03-31 17:48:31 EDT","open":151.58,"high":152.86,"low":150.515,"amount":304183314.85741997,"amplitude":0.015596,"askPrice":153.25,"askSize":132,"bidPrice":150.36,"bidSize":2,"shortable":3,"etf":0,"ttmEps":7.15,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775001600000},"marketStatusCode":4,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":150.36,"dividendRate":0.030547,"preHourTrading":{"tag":"盘前","latestPrice":151.27,"preClose":150.36,"latestTime":"09:26 EDT","volume":10604,"amount":1606554.35424,"timestamp":1774963560832,"change":0.91,"changeRate":0.006052,"amplitude":0.007781},"postHourTrading":{"tag":"盘后","latestPrice":152.75,"preClose":152.75,"latestTime":"17:33 EDT","volume":21512,"amount":3285958.6453600004,"timestamp":1774992792108,"change":0,"changeRate":0,"amplitude":0.001702},"volumeRatio":1.312107,"impliedVol":0.2812,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2622487680","title":"诺华拟斥高达20亿美元收购生技公司Excellergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622487680","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622487680?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:43","pubTimestamp":1774626210,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华将斥高达20亿美元收购生技公司Excellergy，交易预计将于今年下半年完成，但需满足包括获得监管部门批准在内的各项条件。收购协议将包括首期付款及里程碑付款。透过今次交易，诺华将收购Excellergy的候选药物Exl-111，这是一种抗IgE抗体，目前处于早期测试阶段，可补充公司现有的过敏产品组合。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","NVS","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4588","BK4532","BK4585","BK4578","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0208291251.USD","BK4007","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845105","title":"诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845105","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845105?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:36","pubTimestamp":1774597007,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","BK4588","NVS","LU0070302665.USD","IE0002141913.USD","LU0211331839.USD","LU0320765489.SGD","BK1574","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4007","IE00BJT1NW94.SGD","BK1191","01477","BK4585","IE00BFTCPJ56.SGD","BK4578","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622302684","title":"阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302684","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622302684?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:37","pubTimestamp":1774427820,"startTime":"0","endTime":"0","summary":"【阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式】记者3月25日获悉，阿里健康与诺华制药宣布在慢性自发性荨麻疹（CSU）领域达成数字化慢病合作。双方将围绕诺华旗下全球首个口服荨麻疹靶向药瑞米布替尼片（商品名：瑞普多），依托阿里健康的数字化平台能力，提供从疾病科普、用药指导到全周期健康管理的整合式服务。阿里健康依托其长期深耕的“全周期慢病管理体系”，为患者打造一个“院外第二诊室”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684062712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B4R5TH58.HKD","LU0070302665.USD","IE00BJJMRZ35.SGD","BK1502","BK1591","BK1589","LU0208291251.USD","BK4007","BK1515","IE00B2B36J28.USD","BK1501","BK4585","LU0320765489.SGD","00241","BK4532","BK1615","IE00BJT1NW94.SGD","IE0009355771.USD","NVS","BK1189","BK1617","BK1584","IE0002141913.USD","BK1247","BK1142","BK1610","BK1571","IE00BFTCPJ56.SGD","BK4588","BK4578","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063596","title":"诺华国际业务部总裁：中国是引入创新和谋求合作的绝佳之地","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063596","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621063596?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:39","pubTimestamp":1774345140,"startTime":"0","endTime":"0","summary":"自2015年以来，在政策、人才、资本等多重力量的推动下，中国医药创新取得长足发展，创新活力和成果引发全球瞩目。2026年是“十五五”开局之年，“十五五”规划纲要提出，加快生物医药等战略性新兴产业发展。2026年的政府工作报告也提出“推动创新药高质量发展”，并首次将生物医药列入“新兴支柱产业”。宏观政策信号持续释放，产业定位进一步提升，中国医药创新有望迎来新的发展窗口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682667347.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682667347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0002141913.USD","IE00B2B36J28.USD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0211331839.USD","NVS","LU0070302665.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585","BK4007","BK4532","BK4578","BK4588","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621236627","title":"诺华万思瀚：人工智能等新兴技术正进一步放大医疗创新的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2621236627","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621236627?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:07","pubTimestamp":1774231620,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京召开，本届论坛主题为“‘十五五’的中国：高质量发展与共创新机遇”。诺华公司首席执行官万思瀚在“健康中国2030”与大健康产业发展专题研讨会上重点探讨了两个核心议题：医疗健康领域创新投资的重要性，以及如何确保创新在未来持续在中国发展以应对挑战。　　万思瀚强调，人工智能等新兴技术正进一步放大医疗创新的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtt5381419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","BK4532","LU0208291251.USD","159891","IE00B4R5TH58.HKD","NVS","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4007","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","161631","BK4578","LU0211331839.USD","IE0002141913.USD","LU0320765489.SGD","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719156","title":"诺华宣布加大在华投资 预计将投入金额超过33亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719156","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719156?lang=zh_cn&edition=full","pubTime":"2026-03-22 16:13","pubTimestamp":1774167236,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","LU0211331839.USD","LU0208291251.USD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4585","BK4578","LU0320765489.SGD","NVS","BK4007","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4588","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4532","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780632","title":"诺华(NVS.US)拟斥资30亿美元收购Synnovation Therapeutics乳腺癌药物资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780632","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780632?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:58","pubTimestamp":1774004312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华集团同意以最高30亿美元的价格收购Synnovation Therapeutics旗下一款实验性乳腺癌药物，以强化其肿瘤学产品管线。根据市场汇编的分析师预期，诺华目前用于治疗此类乳腺癌的药物Piqray，今年销售额预计将下滑9%，至约3.48亿美元。诺华称，该药物旨在精准靶向肿瘤细胞，同时减少对正常细胞的影响，这种策略有望\"为患者带来更好的耐受性和更持久的获益\"。截至周四，诺华股价年内累计上涨6.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","BK4578","BK4588","BK4007","BK4539","IE00BJT1NW94.SGD","LU0208291251.USD","BK4139","IE00BFTCPJ56.SGD","BK4532","LENZ","BK4585","IE0009355771.USD","LU0320765489.SGD","NVS","LU0070302665.USD","LU0211331839.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786602","title":"诺华以30亿美元收购实验性乳腺癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786602","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786602?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:17","pubTimestamp":1773994655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","IE0002141913.USD","BK4532","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4588","LU0208291251.USD","LU0211331839.USD","LU0320765489.SGD","LU0070302665.USD","BK4578","BK4585","BK4007","IE00BJT1NW94.SGD","NVS","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276284","title":"诺华司库奇尤单抗获得美国FDA批准用于治疗12岁以上儿童中重度化脓性汗腺炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276284","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620276284?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:06","pubTimestamp":1773813987,"startTime":"0","endTime":"0","summary":"人民财讯3月18日电，诺华宣布，司库奇尤单抗已获得美国食品药品监督管理局（FDA）批准，用于12岁及以上儿童中重度化脓性汗腺炎（HS）患者的治疗。司库奇尤单抗作为该人群中唯一获批的IL-17A抑制剂，为HS儿童患者提供了差异化的生物制剂治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675829931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","IE00BJJMRZ35.SGD","BK4578","IE0002141913.USD","LU0208291251.USD","IE00BFTCPJ56.SGD","LABU","IE00B2B36J28.USD","LU0320765489.SGD","NVS","BK4588","LU0070302665.USD","BK4007","IE0009355771.USD","BK4585","IE00BJT1NW94.SGD","LU0211331839.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856698","title":"诺和诺德、诺华、强生、默沙东等“集体豪赌”，口服生物药这么难还要砸？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856698","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856698?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:44","pubTimestamp":1772189087,"startTime":"0","endTime":"0","summary":"2月25日，诺和诺德宣布与麻省理工学院传奇科学家Robert Langer实验室分拆公司Vivtex达成深度合作，交易总额最高达21亿美元，共同开发下一代代谢类药物的口服递送技术。2019年，诺和诺德Rybelsus在美获批上市，成为全球首个口服GLP-1受体激动剂。截至2025年底，其累计销售额已突破百亿美元量级，足以证明口服生物药的巨大潜力。人体本能地阻止大分子进入体内，这是生理保护机制。高盛预测，到2030年口服减重药将占据接近四分之一的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","LU0345770993.USD","LU0882574055.USD","LU0648001328.SGD","LU1430594728.SGD","LU1929549753.HKD","LU0130102774.USD","LU2750360641.GBP","LU0208291251.USD","LU1221951129.SGD","LU0345770308.USD","LU2430703095.HKD","BK4592","LU0477156953.USD","SG9999001176.SGD","LU1244550221.USD","IE00BVYPNW00.USD","LU0130517989.USD","LU1074936037.SGD","LU1732800096.USD","LU2112291526.USD","LU0320765646.SGD","SG9999014542.SGD","LU0058720904.USD","LU1934455194.USD","LU1983299246.USD","SG9999014559.SGD","SG9999001440.SGD","LU1571399168.USD","LU1935042991.SGD","LU1989771016.USD","LU0203347892.USD","BK4585","IE00BZ1G4Q59.USD","BK4581","BK4568","LU1057294990.SGD","BK4550","LU0912757837.SGD","BK4504","LU0683600562.USD","LU1093756168.USD","LU1291159041.SGD","IE0034235303.USD","LU2461242641.AUD","IE00BKVL7J92.USD","LU0466842654.USD","LU0640476718.USD","LU2750360997.AUD","LU0265550946.USD","LU0234572021.USD","LU1066051225.USD","BK4532","LU0211331839.USD","LU1116320737.USD","LU0345769128.USD","SGXZ57979304.SGD","IE0002270589.USD","LU1941712264.USD","LU1718418525.SGD","SG9999002232.USD","LU1496350502.SGD","LU1066051811.HKD","IE00B19Z3581.USD","LU2125154935.USD","IE00BVYPNV92.GBP","LU1032466523.USD","LU0154236417.USD","LU0861579265.USD","LU1116320901.HKD","IE00BLSP4452.SGD","LU0203345920.USD","LU0106261372.USD","LU0234570918.USD","LU0238689110.USD","SG9999014575.USD","SG9999015341.SGD","LU2505996681.GBP","IE00B2B36J28.USD","LU2361044865.SGD","LU2361044949.HKD","LU2471134879.HKD","LU1280957306.USD","LU1244550577.SGD","NVOH","LU2324357040.USD","JNJ","LU0980610538.SGD","LU0345769631.USD","LU0787776722.HKD","LU0985320562.USD","LU1066053197.SGD","LU1674673428.USD","LU1934455277.USD","LU2430703178.SGD","LU2602419157.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2471134796.USD","BK4599","IE0001KFT4U8.USD","LU1934455863.HKD","LU0965508806.USD","LU1674673691.USD","LU2505996509.AUD","IE00BGHQF631.EUR","LU1061106388.HKD","LU0265550359.USD","LU0098860793.USD","LU0965509010.AUD","LU0965509283.SGD","LU1894683348.USD","BK4578","LU0070217475.USD","LU1035773651.USD","LU2023250504.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","LU2089984988.USD","LU0122379950.USD","01276","NVO","NVS","LU1941712348.USD","LU0792757196.USD","LU1037948897.HKD","LU2468319806.SGD","BK4588","LU2471134952.CNY","LU0320765489.SGD","LU0689626769.HKD","LU0889566641.SGD","LU1059921491.USD","LU1989772840.SGD","LU1914381329.SGD","LU1261432733.SGD","LU1778281490.HKD","IE0009355771.USD","IE00B3PB1722.GBP","LU0070302665.USD","LU1699723380.USD","LU1162221912.USD","BK4533","IE00B7SZLL34.SGD","LU0795875086.SGD","LU1732799900.SGD","IE00B42XCP33.USD","IE00BFXG1179.USD","LU0432979614.USD","SG9999001176.USD","IE00BDGV0183.EUR","LU2133065610.SGD","LU1037948541.HKD","IE00B1BXHZ80.USD","LU1201861249.SGD","IE00BBT3K403.USD","LU0124676726.USD","IE00BLSP4239.USD","LU1069347547.HKD","LU2360032135.SGD","LU1506573853.SGD","IE0002141913.USD","LU0114720955.EUR","BK4007","IE00BN8TJ469.HKD","LU2129689431.USD","IE00BFTCPJ56.SGD","LU1974910355.USD","LU2471134523.USD","LU2592432038.USD","IE000M9KFDE8.USD","IE00BJT1NW94.SGD","LU1023059063.AUD","LU2106854487.HKD","SG9999013999.USD","LU0965509101.SGD","LU1244550494.USD","SG9999002224.SGD","LU0795875169.SGD","LU1267930813.SGD","LU2023250843.SGD","LU2129689514.USD","LU1221951046.USD","LU2129689605.HKD","LU1989772923.USD","LU1066051498.USD","LU2430703251.USD","LU1917777945.USD","LU1894683264.USD","LU2361045086.USD","SG9999014567.USD","LU2125154778.USD","LU1032955483.USD","LU0006306889.USD","NVOX","LU2347655156.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","LU0266013472.USD","LU1093756325.SGD","BK4516","LU1196500208.SGD","BK4559","BK4534","MRK","SG9999015358.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614308246","title":"诺华制药拟在德州新建放射性配体疗法生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308246","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614308246?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:02","pubTimestamp":1772024578,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","IE00B4R5TH58.HKD","LU0070302665.USD","IE00BJJMRZ35.SGD","BK1574","LU0208291251.USD","BK4007","IE00B2B36J28.USD","BK4585","LU0320765489.SGD","BK4532","IE00BJT1NW94.SGD","IE0009355771.USD","NVS","IE0002141913.USD","01477","IE00BFTCPJ56.SGD","BK4588","BK4578","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614428702","title":"海量财经｜诺华CEO2.3亿年薪背后：一场业绩、股价与长期价值的精密对赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614428702","media":"海报新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614428702?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:22","pubTimestamp":1772011353,"startTime":"0","endTime":"0","summary":"全球医药行业的聚光灯，在2026年初悄然转向瑞士巴塞尔。跨国制药巨头诺华发布2025财年业绩，全球净销售额545.32亿美元，同比增长8%；营业收入176.44亿美元，同比大增25%，核心营业利润率突破40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602253654131088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765489.SGD","LU0070302665.USD","BK4578","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4588","LU0211331839.USD","BK4532","IE0009355771.USD","BK4585","NVS","IE00BJT1NW94.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614554709","title":"【市场】17个国谈药拟进院，独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4585","BK4588","002793","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","NVOX","NVO","BK4599","01276","NVS","LU1093756168.USD","600276","002653","NVOH","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2612293950","title":"诺华同意以144.6亿卢比向投资财团出售印度子公司70.68%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2612293950","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612293950?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:37","pubTimestamp":1771601820,"startTime":"0","endTime":"0","summary":"诺华  已同意将其在诺华印度有限公司持有的70.68%股份，以144.6亿卢比的价格，出售给由WaveRise Investments、ChrysCapital Fund X和Two Infinity Partners组成的投资财团，从而有效结束了其在2024年2月宣布的战略评估。此次评估聚焦于这家在印度上市的子公司，该公司负责销售处方药、仿制药和非处方药。市场反应迅速：在孟买交易中，诺华印度股价一度上涨19.3%，至996.50卢比，交易价格高于公开要约收购价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnnsse2737863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4585","LU0208291251.USD","IE0009355771.USD","MNDmain","BK4532","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","BK4578","LU0320765489.SGD","IE00B4R5TH58.HKD","NVS","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4588","IE00B2B36J28.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612147565","title":"产业新闻 | 礼来单抗/多肽药物组合达3期临床主要终点；穿越血脑屏障！新锐推进新一代阿尔茨海默病疗法……","url":"https://stock-news.laohu8.com/highlight/detail?id=2612147565","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612147565?lang=zh_cn&edition=full","pubTime":"2026-02-19 07:30","pubTimestamp":1771457447,"startTime":"0","endTime":"0","summary":"礼来单抗/多肽药物组合达3期临床主要终点礼来今日宣布，TOGETHER-PsO临床3b期研究取得积极顶线结果。安全性方面，联合用药相关不良事件总体为轻至中度，与两种药物既往已知安全性特征一致。新锐推进潜在“best-in-class”阿尔茨海默病疗法Korsana Biosciences今日宣布结束隐匿模式并公开亮相。此次合作将整合UNP以人工智能增强的大环肽分子平台与诺华在全球药物开发及商业化方面的能力，共同开发下一代治疗药物，潜在应用方向包括心血管疾病领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021907424697a678e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0820561818.USD","LU0943347566.SGD","LU2063271972.USD","LU1814569148.SGD","LU2237443978.SGD","LU0316494557.USD","IE00BJT1NW94.SGD","LU2237443549.SGD","LU1917777945.USD","IE0005OL40V9.USD","BK4599","LU0786609619.USD","LU2023250330.USD","SG9999014906.USD","LU1868836591.USD","LU2750360997.AUD","LU2746668461.USD","LU0354030511.USD","LU1291159041.SGD","BK4588","BK4533","LU2471134523.USD","LU2112291526.USD","LU0689472784.USD","LU0210536198.USD","LU2168564065.EUR","SGXZ81514606.USD","LU0353189763.USD","LU2324357040.USD","LU0096364046.USD","LU1629891620.HKD","SG9999015986.USD","LU0234572021.USD","IE00BJJMRY28.SGD","LU0289739699.SGD","LLY","IE00B1BXHZ80.USD","LU0097036916.USD","LU2360106947.USD","LU0708995401.HKD","IE00BFTCPJ56.SGD","LU1145028129.USD","IE00BKPKM429.USD","LU0006306889.USD","LU0889565916.HKD","IE00B2B36J28.USD","LU1280957306.USD","LU1720051017.SGD","IE00B4JS1V06.HKD","LU2552382215.SGD","LU0672654240.SGD","LU1974910355.USD","SG9999001176.USD","LU0058720904.USD","SG9999015978.USD","LU0432979614.USD","LU0820562030.AUD","LU2456880835.USD","LU1712237335.SGD","LU2237443622.USD","LU0323591593.USD","LU1057294990.SGD","LU0203201768.USD","LU1267930730.SGD","LU1623119135.USD","LU1720051108.HKD","LU2087625088.SGD","GB00BDT5M118.USD","LU2491049909.HKD","LU1804176565.USD","IE00BJJMRZ35.SGD","LU2361045086.USD","LU2168563687.JPY","LU1868836757.USD","LU2213496289.HKD","IE00B775H168.HKD","LU2896262040.SGD","LU1023059063.AUD","LU0266013472.USD","LU0114720955.EUR","LU0079474960.USD","LU0109391861.USD","LU0354030438.USD","ELIL","LU1127390331.HKD","LU1983299246.USD","LU0094547139.USD","LU2089283258.USD","LU2462157665.USD","LU2468319806.SGD","LU2552382058.USD","LU2471134879.HKD","LU2023251221.USD","LU0820561909.HKD","LU1093756168.USD","LU0238689110.USD","SG9999018865.SGD","LU1868837136.USD","SG9999001176.SGD","LU0456855351.SGD","LU0158827781.USD","LU0964807845.USD","LU2264538146.SGD","LU2237443895.HKD","LU2106854487.HKD","ELIS","IE0009355771.USD","SGXZ51526630.SGD","LU0882574055.USD","LU1232071149.USD","LU0353189680.USD","IE00B1XK9C88.USD","LU1551013342.USD","NVS","LU2491050154.USD","IE00BFSS8Q28.SGD","LU1323610961.USD","LU0385154629.USD","LU0787776722.HKD","LU2746668974.SGD","IE00BWXC8680.SGD","LU1061106388.HKD","SGXZ31699556.SGD","LU1988902786.USD","LU0256863902.USD","IE0002141913.USD","LU0466842654.USD","LU2756315318.SGD","LU0061475181.USD","LU0256863811.USD","LU2089984988.USD","LU2237443382.USD","SG9999014914.USD","LU0823416689.USD","LU0683600562.USD","LU2461242641.AUD","LU0471298694.HKD","LU1551013425.SGD","LU2361044865.SGD","SG9999014880.SGD","LU0640476718.USD","LU0882574139.USD","IE00BK4W5L77.USD","LU0471298777.SGD","LU1366192091.USD","LU0417517546.SGD","SG9999018857.SGD","LU2168564222.USD","LU2237438978.USD","BK4516","LU2108987350.USD","BK4581","LU2168564495.EUR","LU0198837287.USD","LU2361044949.HKD","LU0158827948.USD","BK4585","LU0823434740.USD","BK4007","SG9999017495.SGD","LU2491050071.SGD","IE00BJJMRX11.SGD","LU1093756325.SGD","SG9999015945.SGD","LU2750360641.GBP","SG9999015952.SGD","BK4534","LLYX","LU2168564149.EUR","LU0823434583.USD","IE00B4R5TH58.HKD","SG9999014898.SGD","LU1064131342.USD","LU2271345857.HKD","LU2602419157.SGD","LU1989771016.USD","LU2417539215.USD","LU2357305700.SGD","SGXZ57979304.SGD","IE00BK4W5M84.HKD","LU1548497426.USD","LU2111349929.HKD","LU2089284900.SGD","IE00BFSS7M15.SGD","LU0122379950.USD","LU1035775433.USD","IE00BJLML261.HKD","LU2471134796.USD","LU2265009873.SGD","LU2211815571.USD","LU1069344957.HKD","SGXZ99366536.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443465.HKD","LU2756315664.SGD","LU2028103732.USD","LU0320765992.SGD","LU2471134952.CNY","IE00B7KXQ091.USD","LU2552382132.HKD","IE0004445015.USD","LU1868836914.USD","LU2023250504.SGD","LLYZ","LU1868837300.USD","LU0225283273.USD","IE00BN29S564.USD","SG9999013999.USD","LU0203202063.USD","IE0004445239.USD","IE00BKDWB100.SGD","LU0106261372.USD","LU0320765059.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2611486068","title":"超级大洗牌！跨国药企中国市场最新排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2611486068","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611486068?lang=zh_cn&edition=full","pubTime":"2026-02-16 23:02","pubTimestamp":1771254130,"startTime":"0","endTime":"0","summary":"1月份，跨国药企基本都披露了2025年业绩。礼来则以45%的增幅，营收达651.79亿美元成功反超默沙东，排名第三。而在中国市场，2025年1月，替尔泊肽降糖和减重两项适应症相继上市。2022年至2024年，阿斯利康与默沙东争夺跨国药企中国区营收的“NO.1”，“销售一哥”的宝座每年轮流坐庄。此外，诺华已宣布在中国建立核药生产基地，以支持“派威妥”等放射性药物在中国市场的长期供应。跨国药企把全球创新好药带到中国，才是最好的市场策略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021623082495414b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CWEB","MCHI","MRK","LLY","BK4585","NVOH","AZN","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4588","CQQQ","DRAG","BK4614","BK4504","ASHR","NVS","BK4599","NVO","NVOX","KWEB","LU0963586101.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","RHHBY","BK4007","ASHS","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2609463565","title":"诺华制药2025财年实现净利润140.56亿美元，同比增加17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609463565","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609463565?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:01","pubTimestamp":1770393679,"startTime":"0","endTime":"0","summary":"2月7日，诺华制药公布财报，公告显示公司2025财年净利润为140.56亿美元，同比增加17.78%；其中营业收入为548.11亿美元，同比增加8.99%，每股基本收益为7.25美元。从资产负债表来看，诺华制药总负债690.20亿美元，其中短期债务57.84亿美元，资产负债比为0.01，流动比率为1.12。机构评级：截至2026年2月7日，当前有24家机构对诺华制药目标价做出预测，其中目标均价为145.67美元，其中最低目标价为109.51美元，最高目标价为175.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207000135a485507c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609554115","title":"诺华制药(NVS.US)全球首创自免新药在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609554115","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609554115?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:48","pubTimestamp":1770360522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月6日，CDE网站显示，诺华制药(NVS.US)的伊利尤单抗(ianalumab)在中国申报上市。伊利尤单抗是诺华收购(MorphoSys)获得的一款靶向B淋巴细胞活化因子受体(BAFF-R)的全人源单抗，具有耗竭B细胞和抑制BAFF-R的双重作用机制，可用于治疗干燥综合征、免疫性血小板减少症(ITP)、系统性红斑狼疮(SLE)等多种自免疾病。该药物是首个完成III期研究的抗BAFF-R抗体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B2B36J28.USD","LU0208291251.USD","BK1191","BK1574","BK4585","LU0320765489.SGD","BK4007","01477","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","IE0002141913.USD","LU0070302665.USD","NVS","IE00BFTCPJ56.SGD","BK4578","BK4532","IE00BJJMRZ35.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609347749?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问，中国不仅已经成为像诺华这样的大型制药公司极为重要的市场，同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日，诺华（NVS.US）首席执行官万思瀚在财报会上表达了上述观点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","159837","IE0002141913.USD","BK4585","LU0320765489.SGD","IE00BJT1NW94.SGD","BK4532","BK4578","NVS","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4588","LU0208291251.USD","IE00B4R5TH58.HKD","LABU","IE00B2B36J28.USD","IE0009355771.USD","LU0070302665.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608013353","title":"仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2608013353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608013353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:48","pubTimestamp":1770191316,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月4日美股盘前，诺华制药公布2025年第四季度业绩。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物将进一步受到仿制药竞争冲击。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击，首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华已承诺在美国新建七处生产设施，这是其斥资230亿美元扩大该国制造规模计划的一部分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0070302665.USD","BK4585","LU0211331839.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4588","IE00BFTCPJ56.SGD","BK1191","01477","BK4007","IE0009355771.USD","LU0320765489.SGD","BK4578","LU0208291251.USD","BK4532","IE00B4R5TH58.HKD","NVS","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.0153},{"period":"1month","weight":-0.1083},{"period":"3month","weight":0.0839},{"period":"6month","weight":0.1415},{"period":"1year","weight":0.3357},{"period":"ytd","weight":0.0906}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0787},{"period":"3month","weight":-0.0801},{"period":"6month","weight":-0.0546},{"period":"1year","weight":0.1373},{"period":"ytd","weight":-0.0732}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":-0.002777},{"month":4,"riseRate":0.72,"avgChangeRate":0.018717},{"month":5,"riseRate":0.68,"avgChangeRate":0.009252},{"month":6,"riseRate":0.576923,"avgChangeRate":0.011998},{"month":7,"riseRate":0.692308,"avgChangeRate":0.011407},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}